BABB enters the final days of April as a sub-dollar micro-cap with almost no short-selling pressure and a freshly filed Q1 — the most relevant tension being the gap between a stock that dipped this week and a dividend score that quietly ranks among the best in the universe.
The price picture is modest but not alarming. BABB closed at $0.907 on April 28, down roughly 0.3% on the day and the week, though the one-month trend tells a better story — the stock is up nearly 79% over the past month. The RSI sits at a neutral 46, suggesting neither overbought nor oversold conditions after that run. With a market cap just under $6.6 million, this is firmly micro-cap territory, and liquidity is thin.
Positioning in the lending market is essentially a non-story. Short interest data is stale — the most recent ORTEX estimate dates from late February — but even at that point, fewer than 4,200 shares were short, a figure so small it barely registers. Availability in the lending pool has been ample for most of the past year, with the lending pool only tightening briefly in late 2025. Borrow costs, last recorded in early February at around 2.3%, had already fallen sharply from the 5–6% range that persisted through much of 2025. The ORTEX short score registers at 25.6, and while its short score percentile ranks in the 97th percentile of the universe, that is a reflection of the extremely low absolute level of short activity — not a warning of impending squeeze pressure. There is almost nothing here for a short seller to work with.
The most noteworthy signal on BABB this week is the dividend score. It ranks at the 75th percentile — a notable figure for a company of this size trading below $1. Last dividend payments were quarterly $0.01 cash dividends distributed through mid-2022. There is no confirmed forward dividend data, and the dividend history is now stale by over three years, so the score likely reflects the company's historical consistency rather than an active payout programme. It is worth flagging but not overinterpreting.
The fundamental backdrop is thin on coverage. No analyst tracks BABB formally, and there are no price targets or consensus estimates to assess. The company filed its Q1 fiscal 2026 10-Q on April 13 and reported results on April 9, which produced a modest 1% one-day price gain and held that gain over the following five days. Prior quarterly releases followed a similar pattern — small positive day-one reactions in the 1–2% range, no volatility spike. The SEC proxy filing from April 21 points to a shareholder meeting on June 3, which may draw some incremental attention. Ownership is heavily concentrated: the two largest individual holders — Michael Evans (19.7% of shares) and Michael Murtaugh (13.3%) — account for a third of the company between them, with Camelot Event-Driven Advisors holding a further 6.6%. No changes in those positions have been reported recently.
The June 3 annual meeting is the clearest near-term catalyst to watch, alongside any disclosure of Q2 trading conditions — particularly whether franchise royalty revenue held up after the Q1 sales decline flagged in recent filings.
See the live data behind this article on ORTEX.
Open BABB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
